Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy.

Keywords: Secondary acute myeloid leukemia; overall survival; daunorubicin; cytarabine; Haploidentical allogeneic stem cells transplantation EN Secondary acute myeloid leukemia overall survival daunorubicin cytarabine Haploidentical allogeneic stem cells transplantation 1355 1357 3 08/08/23 20230701 NES 230701 Acute myeloid leukemia (AML) is a heterogeneous disease characterized by an excessive proliferation of myeloid precursors in the blood and the bone marrow. However, a few studies have pointed out a greater risk of t-MDS/AML as a late complication of PRRT/peptide receptor chemo radionuclide therapy. Concomitant radiosensitizing chemotherapy with PRRT/PRCRT still plays an important debulking role in NEN patients with high disease burden or biologically aggressive disease, thus t-AML will continue to remain an important issue, particularly in this group of patients. [Extracted from the article]